An ISO 9001 & ISO 13485 Certified Company

Date: November 13, 2025

To, **BSE Limited ("BSE"),** Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001	To, **National Stock Exchange of India Limited ("NSE")** "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051
BSE Scrip code: 543399	**NSE Symbol: TARSONS**

Sub: Investor Presentation for the second quarter and half year ended September 30, 2025

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation for the second quarter and half year ended September 30, 2025.

The Presentation will also be uploaded on the Company's website at www.tarsons.com.

We request you to kindly take the same on your records.

Thanking You,

Yours faithfully,
For Tarsons Products Limited

SANTOSH KUMAR AGARWAL

Digitally signed by SANTOSH KUMAR AGARWAL
Date: 2025.11.13 00:09:34 +05'30'

Santosh Kumar Agarwal
CFO, Company Secretary and Compliance Officer
ICSI Membership No. A44836

Encl: As above

TARSONS PRODUCTS LIMITED

Investor Presentation
November 2025

TRUST
DELIVERED

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Tarsons Products Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

Q2 & H1FY26 Financial & Operational Highlights

Q2 & H1FY26 Key Operational Highlights





Q2 & H1FY26 Standalone Financial Highlights

Revenue (in Rs. crs)



EBITDA^ (in Rs. crs)



Profit After Tax (in Rs. crs)



Cash PAT# (in Rs. crs)



Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



- Impact on PAT due to accelerated depreciation and finance costs related to the new facilities at Panchla and Amta, with revenues expected to accrue in subsequent years.
- EBIDTA for H1FY26 **grew by 19%** on a Y-o-Y basis with margin expansion of 390 bps
- Cash PAT for H1FY26 **grew by 19%** on a Y-o-Y basis

#Cash PAT = PAT + Depreciation

^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit

Q2 & H1FY26 Consolidated Financial Highlights

Tarsons TRUST DELIVERED

Revenue (in Rs. crs)



EBITDA^ (in Rs. crs)



Profit After Tax (in Rs. crs)



Cash PAT# (in Rs. crs)



Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



- Impact on PAT due to accelerated depreciation and finance costs related to the new facilities at Panchla and Amta, with revenues expected to accrue in subsequent years.
- EBIDTA for H1FY26 **grew by 18%** on a Y-o-Y basis with margin expansion of 300 bps
- Cash PAT for H1FY26 **grew by 21%** on a Y-o-Y basis

#Cash PAT = PAT + Depreciation

^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit

Bridge between Standalone & Consolidated PAT – H1FY26

(in Rs. crs)



Management Commentary

Aryan Sehgal
Promoter and Whole time Director

Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said:

"Consolidated Revenue for H1FY26 stood at ₹193.7 crore, reflecting a growth of 5.2% year-on-year. EBITDA grew by 18.4% YoY to ₹52.1 crore compared to ₹44.0 crore in H1FY25. PAT witnessed a decline primarily due to accelerated depreciation and higher finance costs arising from the capitalization of new facility at Panchla, whose revenue contribution will commence in the coming years. Cash PAT for H1FY26 stood at ₹47.5 crore, representing a robust 20.8% YoY growth.

With expanded capacities and the addition of new products, we expect to significantly increase our addressable market, driving sustained revenue growth in the years ahead. Backed by decades of experience in the plastic labware industry and the strong brand equity of Tarsons, we remain confident of a swift ramp-up of the new facilities from FY27 onwards, contributing meaningfully to overall revenue growth and margin expansion through operating leverage.

We remain committed to the long-term growth prospects of the industry and continue to invest through the current down cycle to strengthen our capacities and capabilities, positioning the company for sustainable growth over the next three to five years."

Q2 & H1FY26 Standalone Profit & Loss Statement

Particulars (in Rs. Crs)	Q2FY26	Q2FY25	Y-o-Y	H1FY26	H1FY25	Y-o-Y
Revenue from Operations	**80.5**	**80.1**	**0.5%**	**151.8**	**145.0**	**4.7%**
Cost of Goods Sold	21.9	22.9		42.3	41.0	
Gross Profit	**58.6**	**57.2**	**2.6%**	**109.5**	**104.0**	**5.3%**
Gross Margin (%)	**72.8%**	**71.4%**	**150 bps**	**72.2%**	**71.7%**	**40 bps**
Employee Cost	11.8	10.9		23.7	21.6	
Other Expenses	20.7	22.8		37.4	41.9	
EBITDA^	**26.1**	**23.5**	**11.3%**	**48.4**	**40.5**	**19.4%**
EBITDA Margin (%)	**32.5%**	**29.3%**	**320 bps**	**31.9%**	**28.0%**	**390 bps**
Depreciation	20.2	12.0		37.9	20.9	
Other Income	7.3	10.7		11.9	15.5	
EBIT	**13.3**	**22.2**	**-40.1%**	**22.3**	**35.1**	**-36.4%**
Finance Cost	4.4	4.7		8.7	8.9	
Profit before Tax	**8.9**	**17.5**	**-49.3%**	**13.7**	**26.2**	**-47.9%**
Tax	2.3	4.6		3.6	6.8	
Profit After Tax	**6.5**	**12.9**	**-49.5%**	**10.1**	**19.4**	**-47.9%**
PAT Margin (%)	**8.1%**	**16.1%**	**-800 bps**	**6.7%**	**13.4%**	**-670 bps**
EPS (Rs)	1.2	2.4		1.9	3.6	
Cash PAT#	**26.7**	**24.9**	**7.3%**	**48.0**	**40.3**	**19.1%**

#Cash PAT = PAT + Depreciation

^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit

Q2 & H1FY26 Consolidated Profit & Loss Statement

Particulars (in Rs. Crs)	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Revenue from Operations	**102.3**	**99.2**	**3.1%**	**193.7**	**184.0**	**5.2%**
Cost of Goods Sold	33.2	32.6		62.5	60.3	
Gross Profit	**69.1**	**66.6**	**3.7%**	**131.2**	**123.7**	**6.0%**
Gross Margin (%)	**67.5%**	**67.1%**	**40 bps**	**67.7%**	**67.2%**	**50 bps**
Employee Cost	17.8	16.1		35.7	32.2	
Other Expenses	23.8	25.2		43.3	47.5	
EBITDA^	**27.4**	**25.3**	**8.4%**	**52.1**	**44.0**	**18.4%**
EBITDA Margin (%)	**26.8%**	**25.5%**	**130 bps**	**26.9%**	**23.9%**	**300 bps**
Depreciation	22.5	14.0		42.4	25.0	
Other Income	5.8	8.4		9.1	11.3	
EBIT	**10.8**	**19.7**	**-45.4%**	**18.9**	**30.3**	**-37.8%**
Finance Cost	5.2	4.8		10.2	9.1	
Profit before Tax	**5.6**	**14.9**	**-62.4%**	**8.6**	**21.2**	**-59.3%**
Tax	2.3	4.6		3.5	6.9	
Profit After Tax	**3.3**	**10.3**	**-67.7%**	**5.1**	**14.3**	**-64.4%**
PAT Margin (%)	**3.2%**	**10.4%**	**-710 bps**	**2.6%**	**7.8%**	**-510 bps**
EPS (Rs)	0.6	1.9		1.0	2.7	
Cash PAT#	**25.8**	**24.3**	**6.1%**	**47.5**	**39.4**	**20.8%**

#Cash PAT = PAT + Depreciation

^ EBITDA for Q2FY25 and H1FY25 is after including the one-time expenses of Rs. 6.3 crores and Rs. 9.3 crores respectively relating to provision for damage to machinery during transit

Consolidated Balance Sheet

Assets (in Rs. Crs)	Consolidated	
	Sep-25	Mar-25
Non-Current Assets	**909.6**	**837.5**
Property Plant & Equipment	504.1	455.1
CWIP	251.0	232.9
Other Intangible assets	29.7	31.7
Right of use assets	16.9	16.7
Goodwill	32.5	32.5
Financial Assets		
Other Financial Assets	7.4	4.5
Current Tax Assets (Net)	3.9	3.5
Other Non Current Assets	64.1	60.5
Current Assets	**254.1**	**242.6**
Inventories	135.4	126.0
Financial Assets		
(i) Trade receivables	72.5	79.6
(ii) Cash and cash equivalents	25.9	25.1
(iii) Bank balances other than (ii)	5.4	0.5
Other Financial Assets	0.1	0.1
Other Current Assets	14.8	11.2
Total Assets	**1,163.7**	**1,080.0**

Equity & Liabilities (in Rs. Crs)	Consolidated	
	Sep-25	Mar-25
Total Equity	**626.6**	**630.2**
Share Capital	10.6	10.6
Other Equity	616.0	619.6
Non-Current Liabilities	**289.3**	**274.1**
Financial Liabilities		
(i) Borrowings	214.6	204.9
(ii) Lease Liabilities	7.2	7.4
(iii) Other Financial Liabilities	0.2	0.2
Provisions	0.2	0.2
Other Non Current Liabilities	57.8	52.0
Deferred Tax Liabilities	9.3	9.4
Current Liabilities	**247.8**	**175.7**
Financial Liabilities		
(i) Borrowings	170.4	123.7
(ii) Trade Payables	14.1	15.7
(iii) Lease Liabilities	3.8	3.2
(iv) Other Financial Liabilities	45.2	20.5
Other Current Liabilities	9.7	7.2
Current tax liabilities (net)	0.2	0.3
Provisions	4.5	5.1
Total Equity & Liabilities	**1,163.7**	**1,080.0**

Abridged Consolidated Cash Flow Statement

Particulars (in Rs. Crs)	Consolidated	
	H1FY26	H1FY25
Net Profit Before Tax	**8.6**	**21.2**
Adjustments for: Non -Cash Items / Other Investment or Financial Items	46.3	38.8
Operating profit before working capital changes	**55.0**	**60.0**
Changes in working capital	-6.6	-25.1
Cash generated from Operations	**48.3**	**34.9**
Direct taxes paid (net of refund)	-3.9	-12.9
Net Cash from Operating Activities	**44.5**	**22.0**
Net Cash from Investing Activities	**-78.3**	**-57.7**
Net Cash from Financing Activities	**32.1**	**38.6**
Net Decrease in Cash and Cash equivalents	**-1.7**	**2.8**
Add: Cash & Cash equivalents at the beginning of the period	25.1	17.1
Exchange difference on translation of foreign currency	2.5	0.0
Cash & Cash equivalents at the end of the period	**25.9**	**20.0**

- Net cash from operating activities increased from 22 crs in H1FY25 to 44.5 crs in H1FY26, **growth of more than 100% Y-o-Y,** indicating efficient working capital management & cash conversion cycle
- Cash flow from operations / EBIDTA **stood healthy at 85%** compared to 50% in H1FY25

Tarsons
TRUST DELIVERED

About Tarsons

Tarsons – at a Glance



One of the **leading Indian labware company** engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments)

Products used in laboratories across **research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies and hospitals**

40+ years of experience in the life sciences industry delivering trusted high-quality products.

Robust market share in the highly fragmented Indian labware market*

Diversified product portfolio with **2,000+ SKUs across 350 product segments**

6 vertically integrated manufacturing facilities in West Bengal

Pan-India distribution network with long-standing relationships with the distributors

One of the few players in India to have a **global reach**# in the labware market with 45+ authorized distributors & partners **supplying products to over 40 countries**

*Approximately 9-12% as per Frost & Sullivan Industry Report 2021
#As per Frost & Sullivan Industry Report 2021

Our Journey

1983
Incorporation of TPPL with manufacturing of **reusable plastic products**

1984
Commenced **production of Pipette Tips**, thereby creating a high-quality import substitute

1987
Expanded product line by initiating manufacturing of Centrifuge Tubes

2002
Pioneered the first fully robotic clean room plant for manufacturing molecular biology consumables

2009
Obtained ISO 9001:2015 certificate for manufacturing facility

2012
Established manufacturing facility expanding into production of fully automatic centrifuge tubes, and cryogenic vials in Dhulagarh

2018
Obtained ISO 13485:2016 / NSEN certificate for manufacturing facility

2019
Established line for PCR products in Jalan Industrial Complex at Jangalpur

2021 & 22
Acquired 5 acres land in Panchla & 6 acres land in Amta for capacity expansion, introduction of new product lines, backward integration & fulfillment center

Got listed on Stock Exchanges

2024
Product portfolio expansion & adding depth in existing product basket

Acquisition of European Entity Nerbe

Leading Indian Labware Supplier

Trusted Brand for high quality products in the plastic labware market with 40+ years vintage in the industry

Expertise in production of a wide range of labware products & **amongst the top 3 players** with a robust market share*

Ability to offer differentiated, user friendly, reliable quality & cost-effective products has **enabled strong brand recognition & customer loyalty**

Individual product brands like **Maxipense, Spinwin, Cryochill** are well- recognized by the scientific community

Pioneered the first fully automated plant for manufacturing molecular biology consumables

In-house engineering team driving innovation & ensuring exceptional liquid handling performance across the liquid handling products

Source*: As per Frost & Sullivan Industry Report 2021

Our Competitive Edge

01

Diversified Customers

Long-standing relationships with a diverse set of key end-customers

02

State of Art Facilities

Well-equipped and **advanced automation** driven manufacturing facilities

03

Geographical Presence

Wide geographic reach through a **strong sales & distribution network**

04

Brand & Quality

Leading Indian supplier to the life sciences sector with **strong brand recognition** and **high-quality** diversified products across varied customer segments.

05

Experienced Management Team

Experienced promoter supported by a **highly competent management team** and backed by board of directors comprising of industry veterans

06

Financial Stability

Financial track record with **efficient capital allocation** & streamlined operations ensuring consistent **high profitability**

Catering to diversified End User Industry…

Academic Institutes & Research Organization	National Centre for Biological Sciences	Indian Institute of Chemical Technology	Rain Forest Research Institute	KIIT University	
Pharmaceutical Industry	Dr. Reddy's Laboratories Limited	Enzene Biosciences Limited			
Contract Research Organization	Syngene International Limited	Veeda Clinical Research Limited	TCG Lifesciences Private Limited		
Diagnostics Industry	Dr Lal Pathlabs Limited	Metropolis Healthcare Limited	Molbio Diagnostics Private Limited	Agappe Diagnostics Limited	Mylab Lifesolutions Private Limited
Exports Market	Avantor, Inc	FC-BIOS SDN BHD	iCell INC	Toei Kaisha Limited	

Measures to strengthen customer relations

1. Regular **Feedback from Customers** on quality, delivery & cost
2. Maintaining leading industry & **Regulatory Compliance Standards**
3. **Product Customization** as per the customer's specific needs
4. Adherence to **Quality standards & Safety Protocols** in place
5. **Wide Range of Products**
6. **50-member Sales Team** with deeply entrenched relationships

Our State-of-the-art Manufacturing Facilities…



Units	Land Area (in sq. mts.)	Ownership	Mfg. Revenue Contribution (FY25)
Burroshibtolla I	530	Leased	5.1%
Burroshibtolla II	1,022	Leased	6.3%
Kasba	515	Leased	2.8%
Jangalpur	15,142	Owned	59.1%
Dhulagarh	4,047	Leased	26.7%
Panchla	21,550	Owned	-
Amta	24,280	Owned	-

Upcoming Facility

Key Highlights of the High Precision Manufacturing Process

- ✓ Vertically integrated manufacturing capabilities with **design & development** being carried out **in-house**
- ✓ Automated manufacturing with **use of robotics** & other technologies developed in collaboration with overseas partners
- ✓ **Production process free from human touch** & thus helps to achieve the **desired levels of purity** required for use in life sciences products
- ✓ Manufactured in **clean aseptic environment**; manufacturing process is carried out in fully-validated & 3rd-party certified ISO 8 clean rooms
- ✓ Quality Certifications: **ISO & CE certifications**
- ✓ In Amta, West Bengal, the Company is developing a **new fulfillment center with in-house sterilization as well as manufacturing capability**
- ✓ Company is expanding into **new product categories and capacity expansion at its new production facility in Panchla, West Bengal**

Comprehensive Pan-India Distribution Network

Long-standing relationships with Distributors



Data as on FY25

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness

…with huge underlying Export Market Potential…

Huge Export Opportunity Market

Demand for plasticware expected to **grow at 10% CAGR** for developing markets like APAC & MEA, developed markets like Americas & Europe also expected to grow healthy

Factors such as **supplier reliability,** cultivating new relationships, deepening existing relationships and **meeting demands in timely manner** will enhance the export market share



Rapid increase in demand for plasticware is **providing platform for Indian players** to expand share of export revenues while continuing import substitution at home

Established Indian players can **further expand export market share** on back of high-quality & reliable products with enhanced R&D and independent design & customization capabilities

Domestic companies in India can take advantage of their **competitive pricing** in order to capture larger share of global market

One of the very few players to have a Global Reach

- ✓ As of 31st March 2025, the company sold its products to 40+ countries via 45+ distributors
- ✓ Export operations are a blend of branded and ODM sales
- ✓ Under the ODM model, the product is independently designed & developed by the company as per the requirements given & then sold to the respective brand owners

Export Revenue (INR mn)



Export Revenue Break-up (%)



Key Overseas Clients (ODM Sales)

avantor™

icell

FC-BIOS

Toei Kaisha

…offering Wide Range of High-Quality Products…

*Our products are **made from high-quality medical grade DMF registered resins** which are selected **to minimize additives & reduce potential leachable***

Consumables

55.5% of FY25 Revenues

- Portfolio of products under this category include:
    - Centrifuge ware
    - Cryogenic ware (tubes & accessories)
    - PCR consumables (tubes, plates, and strips)
    - Petri dish
    - Pipettes

Reusables

40.7% of FY25 Revenues

- Portfolio of products under this category include:
    - Bottles & Carboys
    - Beakers
    - Measuring cylinders
    - Racks
    - Others (jars, desiccators etc.)
    - High quality standards maintained to ensure the products are leakage proof through specially designed lip-sealing geometry

Others

3.8% of FY25 Revenues

- Products under this category includes benchtop instrumentation such as:
    - Vortex shakers
    - Centrifuges
    - Pipettors
- These products enable molecular works of cell collection, extraction, simple spin-down and f-tube separation

Offering a **Wide Range of Products** enabling its end-customers to source most of their product needs from a **Single Source**

…diversified product portfolio of Plastic Labware

Consumables (55% of FY25 Sales)

Pipette Tips

Mostly used in research work for transferring small volume of liquids with high precision

Centrifuge Tubes

Perfect for versatile applications, these are used for storage, spinning down & separation of colloidal solution

Petri Dishes

- Mostly used in culture of microbes & sensitivity assays
- Used once & discarded which optimizes time consumed in washing and sterilizing

Sterile Media Bottles

Suited to preparation & containment of buffers, cultures or prolonged storage of pH sensitive liquids such as culture media

Cryo Vials

Used for storage of biological materials at temperatures as low as -196°C (vapour phase of liquid nitrogen) to 121°C

Storage Vials

Designed for use with samples from -80°C to 121°C. Used for storage of PCR reagents, enzymes & other diagnostics, biochemical reagents or samples

Serological Pipette

Disposable pipettes for tissue culture, microbiological and various research applications. Certified DNase, RNase, and Pyrogen free

Reusables & Others (45% of FY25 Sales)

Bottles

- Used for containment, protection and transportation of various kinds of reagents
- Leakproof, strong and durable

Carboys

Used for media formulation and mixing, aseptic protocols, stirring and storage of intermediates

Beakers

- Used for mixing; graduations are approximate and not intended for accurate liquid measurement
- Economical enough to discard after one use, or strong enough to reuse

Cylinders

Used to measure the volume of a liquids, chemicals, and solutions during daily lab work

Benchtop Instruments

- Wide variety products which include benchtop instrumentation like vortex shakers, centrifuges, pipettors
- Enable molecular works of cell collection, extraction, simple spin-down and f-tube separation

Key Business Strategies

Key Business Strategies

Enhance existing & expand product portfolio

- Focus on **branding & promotion** to enhance visibility in the labware industry to increase brand awareness & loyalty
- **Manufacture New Products** in the cell culture & robotic handled consumables and expand into the import dominated markets of these products
- Leverage the advantage of **"Make in India"** and grow our domestic sales vis-à-vis exports

Enhance manufacturing capacities to leverage growth

- **Expand manufacturing capacities** in popular product categories like liquid handling, centrifuge ware, & cryo ware through additional machines, moulds and ancillary infrastructure
- Acquired 5 acres of land to develop a new manufacturing facility in Panchla, West Bengal to **expand & enter into the new product segment** comprising of cell culture
- Also, acquired 6 acres of land at Amta to develop **fulfilment center, radiation facility and manufacture few products**

Increasing presence in overseas markets

- Plans to **export to ~120 countries in the next 5-10 years** through the extensive experience and proven track record of catering to overseas customers
- Acquired Nerbe, a Hamburg-based distributor specializing in plastic labware products
- Two-pronged approach:
  - **Branded sales** targeting emerging markets such as Asia Pacific, Middle East and South America
  - **ODM sales** to supply products to developed markets such as USA and Europe

Maintain operational efficiency & profitability

- Implemented strategic cost-saving and efficiency improvement processes such as **advanced automation solutions** to improve productivity
- Continue to **invest in automation** in order to avoid human error & consequently **improve throughput**

Experienced Board of Director & Managerial Team

Sanjive Sehgal
Chairman & Managing Director

- Chairman & Managing Director of Tarsons Product Limited
- Has over 40 years of experience in the company

Suresh Prabhala
Non-Executive Director

- Co-founder & Managing Partner at ADV Partners.
- Investment professional with 25+ years of experience. Erstwhile ED and India Head for J.P. Morgan's Asia Special Situations Groups

Mr. Ramanathan Subramanian Arun Kumar
Non-Executive Nominee Director

- Partner & COO at ADV Partners with 25 years of extensive experience in the financial services sector
- Served as Chief Operating Officer – MENA at PineBridge Investments (Bahrain), and Chief Financial Officer at the Sovereign Wealth Fund in Bahrain

Aryan Sehgal
Promoter and Wholetime Director

- Whole-time Director of the company
- Has over 10 years of experience working in the company

Girish Vanvari
Independent Director

- Founder of Transaction Square, Tax, Regulatory & Business Advisory Firm
- Qualified Chartered Accountant with over 27 years of experience in business consulting

Dr. Monjori Mitra
Independent Director

- MBBS degree from Burdwan University,
- Pioneering researcher in the field of vaccines and plays a key role in several national and international advisory boards and working groups on immunization practice guidelines

Santosh Agarwal
CFO & Company Secretary

- Qualified Chartered Accountant & Company Secretary
- Has over 21 years of experience

Divya Momaya
Independent Director

- 22+ years of experience in corporate and secretarial laws, corporate governance, business development
- Previously associated with BSE Ltd. And BSEL Infrastructure Realty Ltd.

Viresh Oberai
Independent Director

- 22+ years experience with Tata Steel
- Conferred with "Udyog Rattan" award from Indian Economics Society

Contribution towards Environmental, Social & Governance

Clean room conditions eliminates all chances of contamination

Productivity optimisation with use of **high automation**

Use of **Medical Grade Plastics**. Products are designed to withstand critical use

NO litigations faced for pollution or degradation of environment over the past five years

NO impact of Climate change

Employee Welfare: Multi-pronged approach towards employee development.

Company has **NOT** witnessed any employee unrest / strikes or lockouts since inception

Some of the CSR activities has been directed towards **TATA Cancer Hospital**

The Board has an optimum combination of Executive and Non-Executive directors

Company has **Clean Track Record** of Liability payments to various stakeholders

Regular **Review & Updation** of policies for change requirements.

Whistleblower policy implemented

Key Takeaways

Leading Indian manufacturer of labware with an established brand & focus on high-quality products

Presence in an industry with double-digit growth potential and multiple growth drivers

Long-standing relationships with distributors catering to a diverse set of end-customers pan-India

Financial profile with Historical strong EBITDA margins & high ROCE

Highly automated state-of-the-art manufacturing facilities churning out quality products

Well-placed to grow domestic & export business through launch of new products & capacity expansion

Thank You

Tarsons Products Limited

CIN: L51109WB1983PLC036510
Mr. Santosh Agarwal – Chief Financial Officer
santosh@tarsons.in

Strategic Growth Advisors Private Limited

CIN: U74140MH2010PTC204285
Mr. Sagar Shroff / Mr. Tanay Shah
sagar.shroff@sgapl.net / tanay.shah@sgapl.net
+91 98205 19303 / +91 98333 91899